The senior neurologist at the University Hospital Center of Nice in France talked about a digital tool developed to monitor disability more accurately in patients with multiple, especially during the early stages of the disease. [WATCH TIME: 5 minutes]
Over a 24-month follow-up, investigators observed increased ganglion cell loss that could potentially be associated with an enhanced risk of developing progression without relapse activity.
The director of the neurology residency program and assistant professor of neurology at the University of South Alabama College of Medicine shared his insights from a year’s worth of using a serum biomarker test for the diagnosis of multiple sclerosis. [WATCH TIME: 5 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the European Committe for Treatment and Research in Multiple Sclerosis.
Data from a US database suggest that patients who switched to eculizumab (Soliris; Alexion) significantly reduced their hospitalization, days hospitalized, and documented comorbidities.
The head of Biogen’s MS and Immunology Department Unit discussed FUSION, a new phase 2, 2-part study assessing the efficacy and safety of BIIB091, an investigational Bruton’s tyrosine kinase inhibitor. [WATCH TIME: 3 minutes]
Over a 6-month period, ofatumumab-treated patients met the primary end point of no change or reduction in the number of gadolinium-enhancing lesions on MRI.
The clinical research director of the UCSF Multiple Sclerosis Center talked about a clinical trial highlighting the therapeutic benefits of longterm treatment with inebilizumab in patients with NMOSD. [WATCH TIME: 4 minutes]
Findings from the OCARINA I study presented at the MSMilan 2023 meeting showed that a 920 mg subcutaneous dose of ocrelizumab was well-tolerated in patients with relapsing or primary progressive multiple sclerosis, with similar exposure to the FDA-approved intravenous dose.
A recent analysis presented at MSMilan 2023 showed significant cognitive and biomarker improvements among patients with progressive multiple sclerosis receiving repeated intrathecal injections of autologous mesenchymal stem cells.
The director of the Multiple Sclerosis Program at UCLA discussed the need to consider HRT among women with MS going through menopause, and how HRT can improve its negative effects. [WATCH TIME: 4 minutes]
A new analysis of the SAkuraMoon study showed that annual relapse rate remained consistently low in satralizumab-treated patients, with high proportions of patients remaining free from relapse, severe relapse, and worsening in disability.
Despite not showing significant associations, those with B cell suppression had longer time to relapse, new MRI activity, and progression independent of relapse activity than those without.
The founder and chief executive officer of Joi Life Wellness Group Multiple Sclerosis Center provided insight on the barriers with expanding precision medicine and the need for additional biomarkers of clinical progression. [WATCH TIME: 3 minutes]
The administration of a subcutaneous 920-mg dose resulted in near-complete suppression of radiological and clinical disease activity as measured up to week 24, similar to the intravenous therapy.
Using a minimally invasive neuromodulation device, patients showed decreases in Overactive Bladder questionnaire symptoms and increases in OAB-q quality of life scores.
A recent analysis of the PREVENT and CHAMPION-NMOSD found no significant differences in safety outcomes for patients with AQP4+ NMOSD who were treated with rituximab prior to starting C5 complement inhibitors in specific timeframes.
Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.
The senior physician and head of the Multiple Sclerosis Centre at University Hospital Basel spoke about his partnership with Octave and their work assessing and validating biomarkers for use in multiple sclerosis. [WATCH TIME: 4 minutes]
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.
The postdoctoral researcher and health psychologist at King's College London spoke at ECTRIMS 2022 about the digital approach to treating fatigue in multiple sclerosis and the lack of available measurements. [WATCH TIME: 3 minutes]
The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the relationship between mood and fatigue in patients with MS. [WATCH TIME: 2 minutes]
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]
The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the most important aspect for improving fatigue in MS. [WATCH TIME: 4 minutes]
The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]
The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about how her patients with pediatric MS have been inspirational to her in her practice. [WATCH TIME: 4 minutes]
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine detailed the next steps in reforming and applying new 2-stage models that improve selection for MS disease-modifying therapies. [WATCH TIME: 6 minutes]
The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia, spoke about the wellbeing of pediatric patients with MS in reference to her presentation at ECTRIMS 2022. [WATCH TIME: 4 minutes]
The assistant professor of medicine at University of Toronto, and neurologist at St. Michael's Hospital spoke about the process of changing or beginning treatment with a variety of disease-modifying therapies in multiple sclerosis. [WATCH TIME: 4 minutes]
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]
